Sign up USA
Proactive Investors - Run By Investors For Investors

Clovis Oncology soars as ovarian cancer drug passes key endpoints in final stage trial

Clovis added it will now submit a New Drug Application within the next four months for a second-line and later maintenance treatment indication
picture of ovaries
Rucaparib is a treatment for women with platinum-sensitive ovarian cancer

Clovis Oncology Inc (NASDAQ:CLVS) rocketed almost 50% as its trial for advanced ovarian cancer treatment rucaparib passed its final stage with flying colours.

A treatment for women with platinum-sensitive ovarian cancer, rucaparib demonstrated improved progression free survival (PFS) in all three indications while it also improved PFS in a blind independent review, which was the secondary endpoint.

Clovis added it will now submit a New Drug Application within the next four months for a second-line and later maintenance treatment indication for all women with platinum-sensitive ovarian cancer who responded to their most recent platinum therapy.

“We are very pleased with these positive ARIEL3 topline results that strongly demonstrate the potential of rucaparib to help women with platinum-sensitive, advanced ovarian cancer,” said Patrick Mahaffy Clovis’s chief executive.

“These results reinforce the potentially foundational role of rucaparib in the management of advanced ovarian cancer, as demonstrated by both investigator review and the blinded independent central review.” 

Shares rose US$27.91 to US$87.88, valuing the group at US$3.95bn.

PhilW.jpg


Register here to be notified of future CLVS Company articles
View full CLVS profile View Profile

Clovis Oncology Inc. Timeline

Related Articles

picture of drug lab
February 07 2017
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use